Despite recoverin being considered a key biomarker for CAR syndrome, the presence of anti-recoverin ARAs is infrequent, with only approximately 5% of CAR patients possessing such antibodies [35, 101]. Here, RCVRN is linked to cancer-associated retinopathy.